Pharmaceuticals Kenya

Kenya Malaria Vaccines Market Analysis, 2024–2034

Kenya Malaria Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Region, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Kenya · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $0.1 Mn Estimated value
Estimate 2025 $0.2 Mn 0.1% of the global market
Projected 2034 $1.3 Mn 694.8% Adds $1.1 Mn over 9 forecast years
CAGR 2025–2034 25.9% Faster than 93% of 180 Pharmaceuticals markets here
Key players 5
  • Kenya is 0.05% of the global market.
  • In Africa, the largest is South Africa at $2.2 Mn.
  • Fastest growing: South Africa at 26.6% a year.
  • Kenya ranks 3rd of 3 by size in Africa.

Market size projection

Kenya

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Malaria Vaccines Market market size by year, Kenya
YearMarket sizeChange that yearSince 2025
2024 (estimate) $0.1 Mn — —
2025 (base) $0.2 Mn +$0.0 Mn —
2026 (forecast) $0.2 Mn +$0.0 Mn +25.9%
2027 (forecast) $0.3 Mn +$0.1 Mn +58.5%
2028 (forecast) $0.3 Mn +$0.1 Mn +99.6%
2029 (forecast) $0.4 Mn +$0.1 Mn +151.2%
2030 (forecast) $0.5 Mn +$0.1 Mn +216.3%
2031 (forecast) $0.6 Mn +$0.1 Mn +298.2%
2032 (forecast) $0.8 Mn +$0.2 Mn +401.4%
2033 (forecast) $1.0 Mn +$0.2 Mn +531.3%
2034 (forecast) $1.3 Mn +$0.3 Mn +694.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $312.5 Mn
  2. North America $166.5 Mn
  3. US $114.6 Mn
  4. APAC $75.7 Mn
  5. Europe $62.7 Mn
  6. Canada $26.0 Mn
  7. China $22.5 Mn
  8. Japan $21.0 Mn
  9. Latin America $12.5 Mn
  10. Middle East $12.5 Mn
  11. Germany $11.0 Mn
  12. UK $7.7 Mn
  13. Brazil $7.8 Mn
  14. France $7.4 Mn
  15. Italy $6.5 Mn
  16. Spain $6.1 Mn
  17. Ecuador $5.8 Mn
  18. India $5.7 Mn
  19. Africa $5.4 Mn
  20. Saudi Arabia $5.0 Mn
  21. Mexico $4.7 Mn
  22. Australia $3.9 Mn
  23. New Zealand $3.6 Mn
  24. Russia $3.3 Mn
  25. South Africa $2.2 Mn
  26. UAE $1.7 Mn
  27. Egypt $1.0 Mn
  28. Philippines $0.8 Mn
  29. Hong Kong $0.5 Mn
  30. Malaysia $0.5 Mn
  31. Singapore $0.5 Mn
  32. Thailand $0.3 Mn
  33. Kenya (this report) $0.2 Mn

The Kenya Malaria Vaccines Market Analysis Executive Summary

Malaria vaccines protect young children in high-risk areas against malaria, a leading cause of child deaths in Africa.

Key segments of the malaria Vaccines market include product (RTS,S/AS01, R21/Matrix-M and Candidates) and region (Sub-Saharan Africa, Asia and Latin America).

Kenya Malaria Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the malaria Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the malaria Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the malaria Vaccines market.

Competitive Landscape for Malaria Vaccines Market in Kenya

The malaria Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Malaria Vaccines Market in Kenya

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for malaria Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Kenya.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Malaria Vaccines right now, from free public sources.

Clinical trials

2 active trials in Kenya

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Sanaria 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 325 papers since 2021 (worldwide)

  1. New sites of vulnerability to stop vivax malaria. Trends in parasitology, 2026
  2. First-in-human trial in Burkinabe adults and children of replication-competent, genetically attenuated PfSPZ-LARC2 Vaccine for malaria. medRxiv : the preprint server for health sciences, 2026
  3. Economic Evaluations for Malaria Vaccines: A Systematic Review. Value in health regional issues, 2026
  4. Preclinical Evaluation of the SMNP-Adjuvanted R21 Malaria Vaccine Across Multiple Mouse Strains. Vaccines, 2026
  5. Transgenic Plasmodium berghei expressing P. vivax pre-erythrocytic antigens SSP3 and SPECT1 to elucidate their efficacy towards vaccine development. PLoS neglected tropical diseases, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Malaria Vaccines in context

Kenya compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.29 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 3.0% of people (2025). World: 10.4% of people (2025). 10th highest of the 17 countries we cover in Africa.[3]

Questions, answered with public data

How many clinical trials on Malaria Vaccines are running in Kenya?
2 studies are recruiting, active or about to start in Kenya.[4]
How much research is published on Malaria Vaccines?
PubMed lists 325 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Kenya. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Malaria Vaccines in Kenya? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Kenya

See all
Same topic, other categories

Related on vaccines and malaria

See the topic